- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
British journal of dermatology. - 182, 5 (2020) , 1279-1281, ISSN: 1365-2133
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2020
- Urheber
-
Mittapalli, Venugopal Rao
Kühl, Thorsten
Kuzet, Sanya Eduarda
Gretzmeier, Christine
Kiritsi, Dimitra
Gaggioli, Cédric
Bruckner-Tuderman, Leena
Nyström, Alexander
- DOI
-
10.1111/bjd.18639
- URN
-
urn:nbn:de:bsz:25-freidok-1656394
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mittapalli, Venugopal Rao
- Kühl, Thorsten
- Kuzet, Sanya Eduarda
- Gretzmeier, Christine
- Kiritsi, Dimitra
- Gaggioli, Cédric
- Bruckner-Tuderman, Leena
- Nyström, Alexander
- Universität
Entstanden
- 2020
Ähnliche Objekte (12)
Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers
Recent advances in understanding and managing epidermolysis bullosa
Dystrophic epidermolysis bullosa - from biochemistry to interventions
Transmembrane collagens - unexplored mediators of epidermal‐dermal communication and tissue homeostasis
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
Inborn errors of immunity and immunodeficiencies: Antibody‐mediated pathology and autoimmunity as a consequence of impaired immune reactions
Gene therapy for epidermolysis bullosa: sticky business
Diversity ofmechanisms underlying latent TGF-[beta] activation in recessive dystrophic epidermolysis bullosa
Dupilumab zur Behandlung der Epidermolysis bullosa acquisita
Treatment of Epidermolysis bullosa acquisita with dupilumab
Inborn errors of immunity and immunodeficiencies: antibody‐mediated pathology and autoimmunity as a consequence of impaired immune reactions
Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers
Recent advances in understanding and managing epidermolysis bullosa
Dystrophic epidermolysis bullosa - from biochemistry to interventions
Transmembrane collagens - unexplored mediators of epidermal‐dermal communication and tissue homeostasis
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
Inborn errors of immunity and immunodeficiencies: Antibody‐mediated pathology and autoimmunity as a consequence of impaired immune reactions
Gene therapy for epidermolysis bullosa: sticky business
Diversity ofmechanisms underlying latent TGF-[beta] activation in recessive dystrophic epidermolysis bullosa
Dupilumab zur Behandlung der Epidermolysis bullosa acquisita
Treatment of Epidermolysis bullosa acquisita with dupilumab
Inborn errors of immunity and immunodeficiencies: antibody‐mediated pathology and autoimmunity as a consequence of impaired immune reactions
Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers
Recent advances in understanding and managing epidermolysis bullosa
Dystrophic epidermolysis bullosa - from biochemistry to interventions
Transmembrane collagens - unexplored mediators of epidermal‐dermal communication and tissue homeostasis
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
Inborn errors of immunity and immunodeficiencies: Antibody‐mediated pathology and autoimmunity as a consequence of impaired immune reactions
Gene therapy for epidermolysis bullosa: sticky business
Diversity ofmechanisms underlying latent TGF-[beta] activation in recessive dystrophic epidermolysis bullosa
Dupilumab zur Behandlung der Epidermolysis bullosa acquisita
Treatment of Epidermolysis bullosa acquisita with dupilumab